|
Monday 8th December 2025 |
Text too small? |
Rua Bioscience is pleased to provide an update on the progress of its pro rata rights offer currently open to eligible shareholders.
To date the Company has received commitments for over $1.5 million from existing shareholders, with a total of $2 million on offer. This demonstrates strong support for Rua’s strategy and the objectives of the capital raise. These commitments reflect the confidence of shareholders in the Company’s commercial progress, operational execution, and long-term growth ambitions in the global medicinal cannabis sector.
The pro rata rights offer remains open until the end of day on Friday, 12 December 2025. Any shareholder that wishes to participate should do so before this date. Full details of the offer, including the timetable and instructions on how to take up rights, are set out in the Offer Document available at www.ruabio.com/capital-raise-november-2025.
Funds raised through the Rights Offer will be applied to working capital and marketing activities to support Rua’s growth opportunities, including the launch and commercialisation of new products across key international markets such as Germany, Australia, the United Kingdom, and Czechia.
ENDS
No comments yet
October 16th Morning Report
CHI - Q3 2026 Operational Update
Devon Funds Morning Note - 14 October 2026
BIT - Transaction in Own Shares
PHL - Operational Update - Q2 FY27
October 14th Morning Report
MCY - Employee Share Scheme - Financial Assistance Notice
PGW - PGG Wrightson FY27 Market Guidance
TEM - Transaction in Own Shares
October 13th Morning Report